Compare Quest Diagnostics Inc (DGX) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Innodata Inc — how do they compare? Quest Diagnostics Inc trades at $237.44 (market cap $26.21B), while Innodata Inc trades at $62.27 (market cap $2.05B). The key difference: Quest Diagnostics Inc is far larger — about 12.8× Innodata Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| DGX | INOD | |
|---|---|---|
Market Cap | $26.21B | $2.05B |
Sector | Health | Technology |
52-Week High | $238.50 | $121.50 |
52-Week Low | $173.49 | $34.45 |
Enterprise Value | $31.97B | $1.80B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
INOD trades at $61.40, down 1.33% today, but maintains a bullish technical signal with oscillators supporting upside momentum. The company reported strong Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and AI-driven demand expansion. Valuation ratios remain elevated with a P/E of 48.62, reflecting high growth expectations.
Outlook is positive given consistent earnings beats and AI sector tailwinds, but risks include premium valuation sensitivity and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
